All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Intellipharmaceutics International Inc., of Toronto, said the FDA provided notification stating the company will not be required to conduct phase III studies of Rexista, its abuse-deterrent version of oxycodone hydrochloride, if bioequivalence to Oxycontin is demonstrated.